We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Patients will receive better support to help them stay in and get back to work in areas of high economic inactivity.
Officers from the MHRA's Criminal Enforcement Unit (CEU) have raided two separate premises as part of an ongoing investigation into an organised criminal network involved in the manufacture and sale of unlicensed weight …
Fake medicines are illegally produced products that may contain incorrect ingredients, no active ingredients, or harmful substances.
As with any medicine, the MHRA will keep the safety and effectiveness of imlunestrant tosylate under close review.
Patients to benefit from improved access to GP appointments under new contract backed by nearly £500 million.
By Richard Stubbs
The 12-week public consultation that opened on Friday 28 November 2025 has closed.
This response agrees with recommendations from the Advisory Council on the Misuse of Drugs (ACMD) in 3 reports about the control and scheduling of 5 medicines.
Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about the consideration of ganaxolone.
Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about zuranolone.
Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about 3 growth hormone agonists.
As with any medicine, the MHRA will keep the safety and effectiveness of brensocatib under close review.
New changes to the GP contract will help protect thousands more children across the country from deadly and highly infectious diseases.
Patients across the country will have better access to NHS dentistry, boosting earlier intervention, prevention and continuity of care.
MHRA has raised new concerns around the PATHWAYS trial looking into the prescription of puberty blockers among young people with gender incongruence.
With all complex clinical trials, MHRA’s top priority is the safety and wellbeing of the trial participants
Innovators across the UK are being offered £20 million in grants for technology designed to reduce harm and death from drug and alcohol addiction.
Zanidatamab is used when the cancer cannot be removed by surgery and has spread to nearby tissues or other parts of the body.
Patients benefit from earlier access to technologies that could improve or save lives, as the MHRA approved 17 per cent more clinical investigations in 2025 compared with 2024, and launches measures to support innovation and…
Findings show that 2,544 deaths in England were associated with cold weather across 3 cold episodes recorded between November 2024 and January 2025.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).